Injection Drug Use and Hepatitis C Virus Infection in Young Adult Injectors: Using Evidence to Inform Comprehensive Prevention

被引:131
|
作者
Page, Kimberly [1 ]
Morris, Meghan D. [1 ]
Hahn, Judith A. [1 ]
Maher, Lisa [2 ]
Prins, Maria [3 ,4 ]
机构
[1] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94105 USA
[2] Univ New S Wales, Kirby Inst, Sydney, NSW, Australia
[3] Univ Amsterdam, Acad Med Ctr, Publ Hlth Serv, Cluster Infect Dis, NL-1105 AZ Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands
基金
英国医学研究理事会;
关键词
hepatitis C virus; prevention; injection drug users; syringe access; counseling and testing; harm reduction; HCV treatment; HCV vaccine; combination prevention; OPIATE SUBSTITUTION THERAPY; SYRINGE PROGRAMS; SAN-FRANCISCO; RISK; NEEDLE; COHORT; SEROCONVERSION; CESSATION; PEOPLE; PREVALENCE;
D O I
10.1093/cid/cit300
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The hepatitis C virus (HCV) virus epidemic is ongoing in the United States and globally. Incidence rates remain high, especially in young adult injection drug users. New outbreaks of HCV in the United States among young adults, in predominantly suburban and rural areas, have emerged and may be fueling an increase in HCV. This paper discusses some key HCV prevention strategies that to date have not been widely researched or implemented, and wherein future HCV prevention efforts may be focused: (1) reducing sharing of drug preparation equipment; (2) HCV screening, and testing and counseling; (3) risk reduction within injecting relationships; (4) injection cessation and "breaks"; (5) scaled-up needle/syringe distribution, HCV treatment, and vaccines, according to suggestions from mathematical models; and (6) "combination prevention." With ongoing and expanding transmission of HCV, there is little doubt that there is a need for implementing what is in the prevention "toolbox" as well as adding to it. Strong advocacy and resources are needed to overcome challenges to providing the multiple and comprehensive programs that could reduce HCV transmission and associated burden of disease worldwide in people who inject drugs.
引用
下载
收藏
页码:S32 / S38
页数:7
相关论文
共 50 条
  • [11] Perinatal hepatitis C virus transmission - Role of human immunodeficiency virus infection and injection drug use
    Armstrong, GL
    Perz, JF
    Alter, MJ
    JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (05): : 872 - 872
  • [12] An outbreak of hepatitis B virus infection among methamphetamine injectors: the role of sharing injection drug equipment
    Vogt, TM
    Perz, JF
    Van Houten, CK
    Harrington, R
    Hansuld, T
    Bialek, SR
    Johnston, R
    Bratlie, R
    Williams, IT
    ADDICTION, 2006, 101 (05) : 726 - 730
  • [13] Injection drug use facilitates hepatitis C virus infection of peripheral blood mononuclear cells
    Resti, M
    Azzari, C
    Moriondo, M
    Betti, L
    Sforzi, I
    Novembre, E
    Vierucci, A
    CLINICAL INFECTIOUS DISEASES, 2002, 35 (03) : 236 - 239
  • [14] Duration of injection drug use affects likelihood of hepatitis C virus infection but not viral persistance
    Edlin, BR
    Kral, AH
    Gee, L
    Seal, KH
    Lorvick, J
    O'Brien, TR
    Tobler, LH
    Andrews, WW
    Phelps, BH
    Busch, MP
    CLINICAL INFECTIOUS DISEASES, 2000, 31 (01) : 314 - 314
  • [15] Recommendations for the management of hepatitis C virus infection in injection drug users
    Grebely, Jason
    Robaeys, Geert
    Bruggmann, Philip
    Aghemo, Alessio
    Backmund, Markus
    Bruneau, Julie
    Byrne, Jude
    Dalgard, Olav
    Feld, Jordan J.
    Hellard, Margaret
    Hickman, Matthew
    Kautz, Achim
    Litwin, Alain
    Lloyd, Andrew R.
    Mauss, Stefan
    Prins, Maria
    Swan, Tracy
    Schaefer, Martin
    Taylor, Lynn E.
    Dore, Gregory J.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2023, 111
  • [16] Acute hepatitis C virus infection in incarcerated injection drug users
    McGovern, Barbara H.
    Wurcel, Alysse
    Kim, Arthur Y.
    zur Wiesch, Julian Schulze
    Bica, Ioana
    Zaman, M. Tauheed
    Timm, Joerg
    Walker, Bruce D.
    Lauer, Georg M.
    CLINICAL INFECTIOUS DISEASES, 2006, 42 (12) : 1663 - 1670
  • [17] Hepatitis C virus infection: Prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999
    Thorpe, LE
    Ouellet, LJ
    Levy, JR
    Williams, IT
    Monterroso, ER
    JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (06): : 1588 - 1594
  • [18] MEDICAL AND LEGAL CONSEQUENCES OF ONGOING DRUG USE AMONG YOUNG INJECTION DRUG USERS INFECTED WITH HEPATITIS C VIRUS
    Barocas, Joshua A.
    Hull, Shawnika J.
    Sosman, James M.
    Sethi, Ajay
    Fangman, John J.
    Westergaard, Ryan
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2013, 28 : S120 - S120
  • [19] Duration of injection drug use affects likelihood of hepatitis C virus infection but not viral persistence.
    Edlin, BR
    Gee, L
    Kral, AH
    Seal, KH
    Lorvick, J
    Tobler, LH
    Andrews, WW
    Phelps, BH
    Busch, MP
    O'Brien, TR
    HEPATOLOGY, 2000, 32 (04) : 543A - 543A
  • [20] Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities
    Hagan, H
    Latka, MH
    Campbell, JV
    Golub, ET
    Garfein, RS
    Thomas, DA
    Kapadia, F
    Strathdee, SA
    CLINICAL INFECTIOUS DISEASES, 2006, 42 (05) : 669 - 672